Literature DB >> 26722383

Characterization of various types of mast cells derived from model mice of familial gastrointestinal stromal tumors with KIT-Asp818Tyr mutation.

Noriko Kajimoto1, Norihiro Nakai1, Mizuka Ohkouchi1, Yuka Hashikura1, Ning-Ning Liu-Kimura1, Koji Isozaki1, Seiichi Hirota1.   

Abstract

Sporadic mast cell neoplasms and gastrointestinal stromal tumors (GISTs) often have various types of somatic gain-of-function mutations of the c-kit gene which encodes a receptor tyrosine kinase, KIT. Several types of germline gain-of-function mutations of the c-kit gene have been detected in families with multiple GISTs. All three types of model mice for the familial GISTs with germline c-kit gene mutations at exon 11, 13 or 17 show development of GIST, while they are different from each other in skin mast cell number. Skin mast cell number in the model mice with exon 17 mutation was unchanged compared to the corresponding wild-type mice. In the present study, we characterized various types of mast cells derived from the model mice with exon 17 mutation (KIT-Asp818Tyr) corresponding to human familial GIST case with human KIT-Asp820Tyr to clarify the role of the c-kit gene mutation in mast cells. Bone marrow-derived cultured mast cells (BMMCs) derived from wild-type mice, heterozygotes and homozygotes were used for the experiments. Immortalized BMMCs, designated as IMC-G4 cells, derived from BMMCs of a homozygote during long-term culture were also used. Ultrastructure, histamine contents, proliferation profiles and phosphorylation of various signaling molecules in those cells were examined. In IMC-G4 cells, presence of additional mutation(s) of the c-kit gene and effect of KIT inhibitors on both KIT autophosphorylation and cell proliferation were also analyzed. We demonstrated that KIT-Asp818Tyr did not affect ultrastructure and proliferation profiles but did histamine contents in BMMCs. IMC-G4 cells had an additional novel c-kit gene mutation of KIT-Tyr421Cys which is considered to induce neoplastic transformation of mouse mast cells and the mutation appeared to be resistant to a KIT inhibitor of imatinib but sensitive to another KIT inhibitor of nilotinib. IMC-G4 cells might be a useful mast cell line to investigate mast cell biology.

Entities:  

Keywords:  Bone marrow-derived cultured mast cell; c-kit gene; exon 17; gastrointestinal stromal tumor; germline mutation; histamine synthesis; imatinib; mast cell neoplasm; model mouse; nilotinib

Mesh:

Substances:

Year:  2015        PMID: 26722383      PMCID: PMC4680328     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  38 in total

1.  Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene.

Authors:  S Hirota; T Okazaki; Y Kitamura; P O'Brien; L Kapusta; I Dardick
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

Review 2.  Pathology of gastrointestinal stromal tumors.

Authors:  Seiichi Hirota; Koji Isozaki
Journal:  Pathol Int       Date:  2006-01       Impact factor: 2.534

3.  A new familial GIST identified.

Authors:  Jerzy Lasota; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2006-10       Impact factor: 6.394

4.  Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features.

Authors:  Ciarán O'Riain; Christopher L Corless; Michael C Heinrich; Denise Keegan; Mihai Vioreanu; Donal Maguire; Kieran Sheahan
Journal:  Am J Surg Pathol       Date:  2005-12       Impact factor: 6.394

5.  Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients.

Authors:  Dae Young Kang; Cheol Keun Park; Jong Sang Choi; So Young Jin; Hyun Jung Kim; Mee Joo; Mi Seon Kang; Woo Sung Moon; Ki Jung Yun; Eun Sil Yu; Haeyun Kang; Kyoung-Mee Kim
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

6.  Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene.

Authors:  H Maeyama; E Hidaka; H Ota; S Minami; M Kajiyama; A Kuraishi; H Mori; Y Matsuda; S Wada; H Sodeyama; S Nakata; N Kawamura; S Hata; M Watanabe; Y Iijima; T Katsuyama
Journal:  Gastroenterology       Date:  2001-01       Impact factor: 22.682

7.  Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa.

Authors:  A Beghini; M G Tibiletti; G Roversi; A M Chiaravalli; G Serio; C Capella; L Larizza
Journal:  Cancer       Date:  2001-08-01       Impact factor: 6.860

8.  Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.

Authors:  K Isozaki; B Terris; J Belghiti; S Schiffmann; S Hirota; J M Vanderwinden
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

9.  Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation.

Authors:  Janet Graham; Maria Debiec-Rychter; Christopher L Corless; Robin Reid; Rosemarie Davidson; Jeff D White
Journal:  Arch Pathol Lab Med       Date:  2007-09       Impact factor: 5.534

10.  Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.

Authors:  L-Y Shih; D-C Liang; C-F Huang; Y-T Chang; C-L Lai; T-H Lin; C-P Yang; I-J Hung; H-C Liu; T-H Jaing; L-Y Wang; T-C Yeh
Journal:  Leukemia       Date:  2007-10-25       Impact factor: 11.528

View more
  3 in total

Review 1.  Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.

Authors:  S Farag; L E van der Kolk; H H van Boven; A C J van Akkooi; G L Beets; J W Wilmink; N Steeghs
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

2.  Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients.

Authors:  Bin Xu; Lujun Chen; Jing Li; Xiao Zheng; Liangrong Shi; Changping Wu; Jingting Jiang
Journal:  Oncotarget       Date:  2016-11-15

3.  LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.

Authors:  Lillian R Klug; Amber E Bannon; Nathalie Javidi-Sharifi; Ajia Town; William H Fleming; Judy K VanSlyke; Linda S Musil; Jonathan A Fletcher; Jeffrey W Tyner; Michael C Heinrich
Journal:  Oncogene       Date:  2018-09-21       Impact factor: 8.756

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.